Lactoferrin Peptide

Origin and Structure

"Lactoferrin peptides" is an umbrella term for a family of short antimicrobial peptides derived by proteolytic cleavage from lactoferrin, an 80-kDa iron-binding glycoprotein abundant in milk, tears, saliva, and neutrophil granules. The most-studied members are lactoferricin — a cationic 25-residue fragment released by pepsin digestion of the lactoferrin N-lobe — and hLF 1–11, an 11-residue synthetic peptide corresponding to the first 11 residues of human lactoferrin and developed as a clinical candidate.

Bovine lactoferricin (LfcinB, residues 17–41 of bovine lactoferrin) is the most extensively characterized member of the family, originally described by Bellamy and Tomita in 1992. It is a strongly cationic amphipathic peptide that forms a twisted beta-sheet and displays antimicrobial activity several orders of magnitude greater than intact lactoferrin — a classic example of a cryptic peptide "released" from a larger protein by digestion.

Mechanism of Action

Lactoferrin-derived peptides operate through two mechanistic themes that overlap depending on the peptide and the target:

• Membrane disruption. The cationic peptides associate with negatively charged lipopolysaccharide on Gram-negative bacteria and with teichoic acids on Gram-positive bacteria, then insert into and destabilize the membrane. Activity extends to fungi, certain viruses, and some protozoa.
• Iron sequestration (for intact lactoferrin; less so for the fragments). The parent protein binds iron with extraordinarily high affinity, denying iron to siderophore-dependent pathogens. The peptide fragments have largely lost this activity but retain membrane-active killing.

In addition to direct antimicrobial action, lactoferrin peptides modulate innate immunity — enhancing neutrophil recruitment, modulating TLR signaling, and influencing NF-κB activation. Several also show antitumor activity in preclinical models, apparently by triggering apoptosis in transformed cells whose altered membrane composition makes them more susceptible to cationic-peptide binding.

Clinical Evidence

hLF 1–11 has advanced the furthest clinically. It was developed by AM-Pharma as a candidate for preventing invasive infections in immunocompromised patients, particularly recipients of hematopoietic stem cell transplants. Phase 1 and early Phase 2 work established safety and tolerability of intravenous administration, though the program did not progress to late-stage approval. Related lactoferricin programs have been investigated for topical antimicrobial, oral mucosal, and ophthalmic applications.

Intact bovine lactoferrin itself, which releases lactoferricin on gastric digestion, has been commercialized as an oral supplement and studied in small trials for indications including Helicobacter pylori eradication (as adjunct to standard triple therapy), iron-deficiency anemia in pregnancy, and prevention of necrotizing enterocolitis in preterm infants. Effect sizes have been modest but reproducible.

Practical Considerations

Most practical human exposure to "lactoferrin peptides" is indirect — through oral lactoferrin supplementation and subsequent gastric release of lactoferricin. Synthetic lactoferricin and hLF 1–11 are primarily research tools and development-stage clinical candidates rather than widely available therapeutics. Bovine lactoferrin is Generally Recognized as Safe (GRAS) for food use and is widely available as a nutraceutical. Typical oral doses range from 100 to 600 mg daily.

The peptides are not orally bioavailable in intact form — their activity after oral intake is local (mouth, stomach, gut) and depends on protease resistance and the local environment. Parenteral use of synthetic lactoferricin analogues remains experimental.

Safety and Regulatory Status

Bovine lactoferrin has an extensive safety record as a food ingredient. Synthetic lactoferrin-derived peptides are not FDA-approved as drugs and exist in the clinical development or research-chemical space. Reported adverse effects of oral lactoferrin are limited to occasional gastrointestinal upset; parenteral fragment exposure in clinical trials has generally been well tolerated at the doses studied.

The Bottom Line

Lactoferrin peptides are a biologically important family of antimicrobial and immunomodulatory peptides with a long research history but a thin list of approved human therapeutics. For most practical purposes, the accessible form is oral bovine lactoferrin — a reasonable nutraceutical with modest evidence across several gut and mucosal indications — rather than the synthetic fragments, which remain primarily research compounds. For the broader antimicrobial peptide context, see our reference pages for cathelicidin and LL-37.